— Know what they know.
Not Investment Advice

KLDO OTC

Kaleido Biosciences, Inc.
1W: +0.0% 1M: +0.0% 3M: +9900.0% YTD: +0.0% 1Y: +0.0% 3Y: +900.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 43 · $4262 mcap · 42M float · 0.0035% daily turnover · Short 59% of daily vol

Balance Sheet Trends

Total Assets
$50M -15.5% ▼
5Y CAGR: +58.6%
Total Liabilities
$40M +1.8% ▲
5Y CAGR: +12.5%
Shareholders Equity
$11M -48.2% ▼
Cash & Investments
$38M -16.8% ▼
5Y CAGR: +69.8%
Total Debt
$22M +3.3% ▲
5Y CAGR: +34.4%
Net Debt
-$17M +33.4% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2017FY2018FY2019FY2020FY2021
— Assets —
Cash$28M$76M$71M$46M$38M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$28M$76M$71M$46M$38M
Net Receivables$45K$5K$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$152K$0$0$254K
Total Current Assets$29M$76M$73M$49M$42M
Property, Plant & Equip.$2M$5M$7M$8M$6M
Goodwill & Intangibles$0$0$0-$2M-$2M
Long-Term Investments$0$0$2M$2M$2M
Other Non-Current Assets$221K$4M$0$5M$2M
Total Non-Current Assets$2M$9M$9M$13M$8M
Total Assets$31M$85M$82M$59M$50M
— Liabilities —
Accounts Payable$864K$3M$2M$5M$6M
Short-Term Debt$0$0$0$3M$16M
Deferred Revenue$3M$7M$7M$498K$828K
Other Current Liabilities$271K$420K-$1M$782K$5M
Total Current Liabilities$4M$11M$10M$17M$30M
Long-Term Debt$15M$15M$20M$18M$6M
Other Non-Current Liab.$56M$998K$3M$4M$4M
Total Non-Current Liabilities$71M$16M$23M$22M$10M
Total Liabilities$74M$27M$33M$39M$40M
— Equity —
Common Stock$10K$24K$30K$36K$43K
Retained Earnings-$44M-$106M-$193M-$274M-$364M
Accumulated OCI-$431K-$1M-$82M$0$0
Total Stockholders Equity-$44M$58M$49M$20M$11M
Total Liabilities & Equity$31M$85M$82M$59M$50M
— Key Metrics —
Total Debt$15M$15M$20M$21M$22M
Net Debt-$14M-$61M-$51M-$25M-$17M
Total Investments$0$0$2M$2M$2M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms